GSK China: what next in the corruption probe?
This article was originally published in SRA
Executive Summary
An investigation by China's Ministry of Public Security into suspected corruption by some executives at GlaxoSmithKline in the country has raised many more questions than have so far been answered. With Chinese officials intimating that GlaxoSmithKline will not be the only company to come under the spotlight, one major question is, how many other firms will be drawn in?